Island Pharmaceuticals Ltd (ASX: ILA) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Island Pharmaceuticals Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$109.06 million
P/E Ratio
N/A
Dividend Yield
0.00%
Shares Outstanding
294.77 million
Earnings per share
-0.023
Dividend per share
N/A
Year To Date Return
-13.95%
Earnings Yield
N/A
Franking
-
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Island Pharmaceuticals Ltd (ASX: ILA)
Latest News
No posts found.
ILA ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Island Pharmaceuticals Ltd
Island Pharmaceuticals Ltd. is a drug research and repurposing company, focused on developing preventative or therapeutic drugs for viral infections. Its Isla101, a drug being repurposed for the prevention and treatment of dengue fever and other mosquito (or vector) borne diseases. The company was founded by David Foster on May 25, 2020 and is headquartered in Camberwell, Australia.
ILA Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 19 Feb 2026 | $0.38 | $0.01 | 2.70% | 379,236 | $0.37 | $0.38 | $0.36 |
| 18 Feb 2026 | $0.37 | $0.01 | 2.74% | 301,811 | $0.37 | $0.37 | $0.36 |
| 17 Feb 2026 | $0.37 | $-0.01 | -2.67% | 248,190 | $0.37 | $0.38 | $0.37 |
| 16 Feb 2026 | $0.38 | $-0.01 | -2.60% | 417,317 | $0.38 | $0.38 | $0.37 |
| 13 Feb 2026 | $0.39 | $0.00 | 0.00% | 287,434 | $0.39 | $0.39 | $0.36 |
| 12 Feb 2026 | $0.39 | $-0.02 | -4.88% | 148,667 | $0.41 | $0.41 | $0.39 |
| 11 Feb 2026 | $0.41 | $-0.01 | -2.41% | 103,457 | $0.42 | $0.42 | $0.41 |
| 10 Feb 2026 | $0.42 | $-0.01 | -2.38% | 47,739 | $0.43 | $0.43 | $0.42 |
| 09 Feb 2026 | $0.42 | $0.00 | 0.00% | 120,296 | $0.45 | $0.45 | $0.42 |
| 06 Feb 2026 | $0.42 | $0.01 | 2.41% | 375,547 | $0.42 | $0.42 | $0.39 |
| 05 Feb 2026 | $0.42 | $-0.01 | -2.38% | 758,164 | $0.43 | $0.45 | $0.38 |
| 04 Feb 2026 | $0.42 | $0.03 | 7.69% | 1,843,933 | $0.43 | $0.50 | $0.41 |
| 30 Jan 2026 | $0.39 | $0.02 | 5.33% | 384,255 | $0.39 | $0.42 | $0.38 |
| 29 Jan 2026 | $0.38 | $-0.02 | -5.13% | 459,198 | $0.40 | $0.40 | $0.38 |
| 28 Jan 2026 | $0.39 | $-0.03 | -7.14% | 730,160 | $0.42 | $0.42 | $0.37 |
| 27 Jan 2026 | $0.42 | $-0.01 | -2.33% | 338,327 | $0.44 | $0.44 | $0.42 |
| 23 Jan 2026 | $0.43 | $0.00 | 0.00% | 80,673 | $0.43 | $0.44 | $0.43 |
| 22 Jan 2026 | $0.43 | $-0.01 | -2.30% | 300,407 | $0.44 | $0.45 | $0.43 |
| 21 Jan 2026 | $0.44 | $-0.01 | -2.27% | 429,644 | $0.44 | $0.47 | $0.44 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 03 Dec 2025 | Christopher Ntoumenopoulos | Buy | 844,568 | $59,119 |
Exercise of options.
|
| 03 Dec 2025 | Christopher Ntoumenopoulos | Exercise | 844,568 | $59,119 |
Exercise of options.
|
| 03 Dec 2025 | Jason Carroll | Exercise | 974,930 | $68,245 |
Exercise of options.
|
| 03 Dec 2025 | Jason Carroll | Buy | 974,930 | $68,245 |
Exercise of options.
|
| 02 Dec 2025 | Jason Carroll | Transfer | 366,666 | $199,832 |
As advised by the company. Transfer executed with third party for participation in previous capital raise
|
| 12 Nov 2025 | Jason Carroll | Issued | 5,000,000 | $500 |
Issue of options.
|
| 12 Nov 2025 | Christopher Ntoumenopoulos | Issued | 2,750,000 | $275 |
Issue of options.
|
| 12 Nov 2025 | David Foster | Issued | 2,000,000 | $200 |
Issue of options.
|
| 30 Oct 2025 | Christopher Ntoumenopoulos | Issued | 346,666 | $51,999 |
Issue of securities.
|
| 30 Oct 2025 | David Foster | Issued | 160,000 | $24,000 |
Issue of securities.
|
| 24 Jul 2025 | Jason Carroll | Buy | 124,250 | $21,122 |
On-market trade.
|
| 19 Mar 2025 | Phillip(Phil) Lynch | Buy | 80,000 | $4,800 |
Exercise of options.
|
| 19 Mar 2025 | Phillip(Phil) Lynch | Exercise | 80,000 | $4,800 |
Exercise of options.
|
| 05 Mar 2025 | David Foster | Buy | 500,000 | $30,000 |
Exercise of options.
|
| 05 Mar 2025 | David Foster | Exercise | 500,000 | $30,000 |
Exercise of options.
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Mr Christopher Ntoumenopoulos | Non-Executive Director | Sep 2024 |
Mr Ntoumenopoulos is the Managing Director at Twenty 1 Corporate, an Australian-based corporate advisory firm. He has experience in financial markets, with over 20 years of raising capital and providing advisory corporate services. Additionally, he has served as a director of ASX listed companies for more than 7 years.
|
| Dr David Foster | Chief Executive OfficerManaging DirectorExecutive Director | Oct 2020 |
Mr Foster has more than 25 years of experience working with early-stage pharmaceutical and biotechnology companies developing a variety of therapeutics including biologics and small molecules. He has represented pharmaceutical, biotherapeutic and diagnostic companies, while in private legal practice and served as intellectual property counsel at Medarex, a mid-sized biotherapeutics company. David co-founded a technology focused law firm, a life science trade association and multiple private biotechnology companies
|
| Mr Jason Alan Carroll | Non-Executive Director | Jul 2025 |
Mr Carroll brings experience as a life sciences executive, with a 34-year career in the industry. His background includes leadership roles at industry giants Johnson & Johnson, Janssen Pharmaceutica, iNova Pharmaceuticals and Bristol-Myers Squibb. Jason has managed roles of increasing responsibility in operations (Pharmaceutical Production Management), sales & marketing (Specialist Medical Representative, Product Management, Sales & Marketing Management & Business Unit Director) and business development (Early Product Development Lead, Associate Director of Market Access, Associate Director of Asia Regional Business Development and Business Licensing & Acquisition). His first country leadership role was as General Manager of Janssen Pharmaceutica Philippines, followed by Managing Director of One J&J Vietnam (including additional responsibilities as SEA Board representative of Janssen Pharmaceuticals Asia-Pacific and SEA Marketing Director of Immunology & Oncology and Global Board membership of the J&J Sustainability Council). He has expertise across pharmaceuticals, biologics, medical devices, OTC & consumer medicines.
|
| Mr Cameron Jones | Chief Financial OfficerCompany Secretary | Dec 2023 |
-
|
| Cameron Jones | Chief Financial OfficerCompany Secretary |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| Dr William James Garner | 41,690,073 | 16.86% |
| Bnp Paribas Nominees Pty Ltd Ib Au Noms Retailclient | 32,786,461 | 13.26% |
| Mr Jason Alan Carroll | 31,100,000 | 12.58% |
| Dr Daniel Tillett | 14,010,000 | 5.67% |
| Dr David C Foster | 6,146,829 | 2.49% |
| Mr Neville James Miles | 5,708,237 | 2.31% |
| Buprestid Pty Ltd Hanlon Family S/F A/C | 2,853,285 | 1.15% |
| Citicorp Nominees Pty Limited | 2,812,395 | 1.14% |
| S3 Consortium Pty Ltd | 2,500,000 | 1.01% |
| Mr Anthony Stephen Cormack | 2,140,000 | 0.87% |
| JAF Capital Pty Ltd | 1,850,000 | 0.75% |
| P R Perry Nominees Pty Ltd Donesk Family A/C | 1,810,000 | 0.73% |
| Mr Alistair Robert Baker | 1,626,101 | 0.66% |
| Lillucy Pty Ltd Lilypily Super Fund A/C | 1,500,000 | 0.61% |
| Mrs Patricia Fernandes Dias De Almeida | 1,453,146 | 0.59% |
| Icader Nominees Pty Ltd Icader Investments A/C | 1,433,333 | 0.58% |
| Mrs Helen Frances Baker | 1,403,720 | 0.57% |
| Grayhawk Capital Pty Ltd | 1,333,333 | 0.54% |
| Mr Yusuf Faruque Ismail & Mrs Ingrid Helen Ismail | 1,300,000 | 0.50% |
| HSBC Custody Nominees (Australia) Limited Gsco Customers A/C | 1,273,508 | 0.52% |
